• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Many Hepatitis C Patients Do Not Have Access To Medicines In India, Group Says

27/07/2016 by Catherine Saez, Intellectual Property Watch Leave a Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Despite being the global leader of generic drug manufacturing, access to hepatitis C treatment in India remains out of reach for a large portion of the population, a civil society group has said in a new paper. The authors call for India to work on a national programme of prevention and treatment of hepatitis, and warn against voluntary licences developed by multinational pharmaceutical companies.

lawyers collectiveLawyers Collective, a civil society group advocating human rights, issued a paper titled “Ensuring Access to HCV Treatment in India; a rights-based analysis [pdf].”

New therapies such as daclatasvir (from Bristol-Myers Squibb) and sofosbuvir (Gilead Sciences) are available in India at much lower prices than in developed countries, for example sofosbuvir is 99 percent cheaper in India than it is in the United States, according to the authors.

However, India has the largest number of poor people in the world, and only 24 percent of the population is covered by some form of health insurance either through government-sponsored schemes or private insurances, the paper said, which makes the prices on the market still unaffordable for the poor.

“As of 2011, India ranked first among the top ten countries with the largest global share of extremely poor,” according to the authors.

The authors also warn against the voluntary licence model of multinational pharmaceutical companies, which they say “are now being propagated” by those companies “as their new business model to promote access to medicines.”

“These approaches are essentially targeted at controlling market competition and restricting any possible government intervention to achieve desired price reduction through the use of TRIPS [World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights] flexibilities.”

For example, the Gilead licences exclude high HCV-burden countries from their scope, and “contain controversial provisions regarding anti-diversion measures, which pose serious ethical breaches” to patient confidentiality, they said.

The paper is co-authored by Anand Grover, Lorraine Misquith, Dr. Samiran Panda  Dr. Saubhik Ghoshᶧ and Giten Khwairakpam.

 

Image Credits: Lawyers Collective

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Catherine Saez may be reached at csaez@ip-watch.ch.

Creative Commons License"Many Hepatitis C Patients Do Not Have Access To Medicines In India, Group Says" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP Policies, Language, Themes, Venues, Asia/Pacific, English, Health & IP, Human Rights, Lobbying, Patents/Designs/Trade Secrets, Regional Policy

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.